Litcius/Paper detail

Safety and pharmacokinetics of Roscovitine (Seliciclib) in cystic fibrosis patients chronically infected with Pseudomonas aeruginosa, a randomized, placebo-controlled study

Laurent Meijer, Geneviève Héry-Arnaud, Cyril Leven, Emmanuel Nowak, Sophie Hillion, Yves Renaudineau, I. Durieu, R. Chiron, Anne Prévötat, Isabelle Fajac, D. Hubert, M. Murris‐Espin, S. Hüge, Isabelle Danner‐Boucher, Bruno Ravoninjatovo, Sylvie Leroy, Julie Macey, T. Urban, G. Rault, Dominique Mottier, Rozenn Le Berre

2021Journal of Cystic Fibrosis18 citationsDOI

Topics & Concepts

MedicinePlaceboCystic fibrosisAdverse effectInternal medicineGastroenterologyPharmacokineticsMucositisPharmacologyChemotherapyPathologyAlternative medicineCystic Fibrosis Research AdvancesLung Cancer Treatments and MutationsAdvanced Breast Cancer Therapies
Safety and pharmacokinetics of Roscovitine (Seliciclib) in cystic fibrosis patients chronically infected with Pseudomonas aeruginosa, a randomized, placebo-controlled study | Litcius